Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00918892 · ClinicalTrials.gov registry record
Assessment of Candidate Protein Expression in Breast Cancer Specimens
A clinical trial, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- 460
- Enrollment target
NCT00918892: Completed study, sponsored by Case Comprehensive Cancer Center.
NCT00918892 is a clinical trial that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 460 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00918892 has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 460 participants
- Enrollment target
Study Summary
RATIONALE: Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer. PURPOSE: This research study is looking at tumor tissue samples from patients who have undergone surgery for breast cancer.
Primary Outcome
Approximately 5 slides of each tumor will be collected to provide sufficient samples for replicate staining, if necessary, as well as a staining for a positive control
Interventions
- GENETIC gene expression analysis
- OTHER laboratory biomarker analysis
- OTHER immunohistochemistry staining method
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2011-01-01 |
| Est. Completion | 2021-09-23 |
What the finished NCT00918892 record still lists
NCT00918892 is an observational study that tracks outcomes without assigning an intervention. The registered 460 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 3 interventions - of which gene expression analysis is the first listed.
NCT00918892 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00918892 about?
NCT00918892 is a clinical study titled "Assessment of Candidate Protein Expression in Breast Cancer Specimens". RATIONALE: Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer. PURPOSE: This research study is looking at tumor tissue samples from patients who have undergone surgery for breast cancer.
What is the current status of trial NCT00918892?
This trial is currently completed. The enrollment target is 460 participants. The study started on 2011-01-01. Estimated completion is 2021-09-23.
What interventions are being tested in trial NCT00918892?
The interventions under investigation include: gene expression analysis (GENETIC), laboratory biomarker analysis (OTHER), immunohistochemistry staining method (OTHER).
Who is sponsoring clinical trial NCT00918892?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- NCT03427736 · 460 participants
Anesthetics and Analgesics in Children
- NCT03819933 · 460 participants · NA
Optimizing Family Counseling for Anticipated Extremely Preterm Delivery
- NCT04621279 · 460 participants
Cool Prime Comparative Effectiveness Study for Mild HIE
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI